预约演示
更新于：2025-04-19
Bimatoprost
贝美前列素
更新于：2025-04-19
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H37NO4 |
InChIKeyAQOKCDNYWBIDND-FTOWTWDKSA-N |
CAS号155206-00-1 |
关联
138
项与 贝美前列素 相关的临床试验IRCT20190210042676N36
Evaluation of safety and efficacy profile of the eyelash booster solution containing stemoxydine and bimatoprost on women with hypotrichosis
CTIS2023-504759-28-00
RANDOMIZED, OPEN LABEL, PARALLEL-GROUP, TWO-ARM, MULTICENTER STUDY WITH CLINICAL ENDPOINT COMPARING PRESERVATIVE FREE BIMATOPROST OPHTHALMIC SOLUTION 0.1 MG/ML AND LUMIGAN® (BIMATOPROST OPHTHALMIC SOLUTION) 0.1 MG/ML IN PATIENTS WITH CHRONIC OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN ONE OR BOTH EYES. - BIM-001
NCT06267274
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Generic Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
100 项与 贝美前列素 相关的临床结果
登录后查看更多信息
100 项与 贝美前列素 相关的转化医学
登录后查看更多信息
100 项与 贝美前列素 相关的专利（医药）
登录后查看更多信息
1,120
项与 贝美前列素 相关的文献（医药）2025-08-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
HPLC method for detecting prostaglandin F2α analogs in cosmetics: Optimization for chromatographic separation and sample preparation
Article
作者: Kim, Hyun-Kyung ; Sung, Min Kyung ; Shin, Eun Jin ; Kim, Hyung Soo ; Woo, In Suk ; Han, Kyoung-Moon ; Kim, You Kyung
Some prostaglandin F2α (PGF2α) analogs, including bimatoprost and tafluprost, are pharmaceutical substances known to cause specific abnormal reactions that promote eyelash growth. However, research on the simultaneous analysis of multiple PGF2α analogs using HPLC-UV or DAD techniques is limited. In this study, a high-performance liquid chromatography (HPLC) method was developed for the simultaneous analysis of 11 PGF2α analogs, optimizing both the analytical column and sample preparation method. Five columns with varying particle sizes, lengths, and packing types were compared to select the optimal analytical column. The separation efficiency of the columns was confirmed by comparing their chromatographic parameters, including retention time, resolution, number of theoretical plates, and height equivalent to a theoretical plate. Solid-phase extraction (SPE) was used to pretreat cosmetic samples, and the washing solvent and cartridge type for the SPE process were optimized. The established HPLC method was validated in terms of linearity, limits of detection and quantification, recovery, accuracy, and precision. The verified analytical method was applied to eyelash serums currently available in the market, and norbimatoprost was detected in one product. The HPLC method proposed in this study may help prevent the distribution of cosmetics containing illegal PGF2α analogs.
2025-05-01EUROPEAN JOURNAL OF PHARMACOLOGY
Treatment of glaucoma with drug-loaded contact lenses: A systematic review and meta-analysis
Review
作者: Cao, Wenbo ; Li, Jia ; Ren, Cong ; Yu, Mingkun ; Guo, Bin ; Zhang, Diya ; Wang, Xuan ; Bi, Hongsheng ; Xu, Zihang
OBJECTIVE:
This study is a systematical review regarding the glaucoma treatment with drug-loaded contact lenses. The effectiveness and safety about that were summarized, which providing effective suggestions and guidance for clinical research.
METHODS:
The studies published up to May 1, 2024 on the treatment of glaucoma with sustained-release contact lenses were searched from CNKI, Wanfang Data, VIP, PubMed, Embase, Cochrane Library, and Medline. CAMARADES was used to evaluate literature quality. The safety, endpoints of intraocular pressure reduction (IOPR) and duration of intraocular pressure (IOP) decline during glaucoma treatment were analyzed by means of qualitative and quantitative methods. The protocol registration number is CRD42024487157.
RESULTS:
47 studies were included. In clinical trials, glaucoma patients showed a 50% reduction in IOP and no corneal tissue destruction after wearing contact lenses. In animal experiments, the endpoint IOPR [MD = 0.58, 95%CI (0.37, 0.80), P < 0.00001] of the medicated contact lenses group was significantly better than that of the eye drops group. Subgroup analysis showed that contact lenses loaded with timolol (TML), with TML + dorzolamide, and with TML + latanoprost, which compared to eye drops, had a better effect on reducing IOP, while contact lenses loaded with puerarin, latanoprost, and TML + bimatoprost showed no statistical difference. Most studies demonstrated the duration of IOP reduction and drugs release in vitro for ≥3 days during contact lenses treatment.
CONCLUSION:
Most drug-loaded contact lenses exhibit excellent effectiveness and safety. The nanoparticle-loaded contact lenses containing TML for glaucoma treatment is recommended in future clinical research.
2025-04-01DRUGS
Safety and Longevity of Intraocular Pressure Control After Bimatoprost Implant Administration: Interim Analysis of a Phase 3b Clinical Trial (TRITON)
Article
作者: Gous, Petrus ; Slabaugh, Mark ; Lascaratos, Gerassimos ; Caldwell, Delmar ; Wirta, David ; Gupta, Shailesh ; Bejanian, Marina ; Wallace, Dana ; Moster, Marlene ; Brinkmann, Christian ; Park, Abraham ; Christie, William C. ; Craven, E. Randy ; Misheva, Aneta ; Bicket, Amanda ; Grupcheva, Christina ; Kerr, Nathan ; Dzhelebov, Dimitar ; Silverstein, Steven M. ; Bicket, Amanda K. ; Walters, Thomas ; van Oterendorp, Christian ; Raczynska, Dorota ; Luebke, Jan ; Sarkisian, Steven ; Khaimi, Mahmoud ; Moyes, Andrew ; Maram, Jyotsna ; Basha, Mahdi ; Penkov, Milen ; Lind, John ; Cagini, Carlo ; Evans, Richard ; Teper, Slawomir ; Robinson, Michael R. ; Paauw, James ; Nolan, Daniel ; Lupinacci, Anahi ; Bourne, Rupert ; Schargus, Marc ; Segal, Bruce ; Martin, Elizabeth ; Dubois, Vincent ; Silverstein, Steven ; Sims, Annette ; Scorcia, Vincenzo ; Fichtl, Marek ; Christie, William ; Lerner, Simon Fabian ; Perez, Bernard ; Lubke, Jan ; Alaghband, Pouya ; Duzman, Eran ; Kolko, Miriam ; Ivanova, Stanislava ; Oddone, Francesco ; Zeolite, Carlos Ignacio ; Paul, Matthew ; Berdahl, John ; Cheeseman, Robert ; Santos, Rodrigo ; Gutmark, Ron ; Bercovich, Gabriel ; Vingolo, Enzo M. ; Moroi, Sayoko ; Daskalov, Veselin ; Zalewski, Dominik ; Milano, Giovanni ; Pu, Yongjia ; Pavicic-Astalos, Jasna ; Walman, Gerald ; Jerkins, Gary ; Wells, Tony ; Patel, Hemang ; Yanev, Petar ; Anguelov, Botio ; Gentile, Carolina ; Cantor, Louis ; Jiao, Jenny ; Hristozov, Valentin ; Topchiyska, Malina ; Jorgensen, Adam ; Cisiecki, Slawomir ; Blasberg, Robert ; Gous, Petrus N. J. ; Ansari, Husam ; Levin, Samantha ; Helsdingen, Nicolaas van ; Hopes, Marina ; Elfervig, John ; Brinkmann, Christian K. ; Bettis, Daniel ; Kubal, Aarup ; Shah, Manjool ; Logan, Dwayne ; Kammer, Jeffrey ; Nguyen, Ashley ; Hendrix, Jason
BACKGROUND:
Bimatoprost implant 10 µg is an intracameral, biodegradable implant that slowly releases bimatoprost to lower intraocular pressure (IOP). This study was designed to evaluate safety and the duration of the IOP-lowering effect after single and as-needed repeat administration of the bimatoprost implant in patients with open-angle glaucoma (OAG) and ocular hypertension (OHT).
PATIENTS AND METHODS:
This study is an interim analysis of an ongoing, prospective, open-label, multicenter study in patients with OAG or OHT who are inadequately managed with topical IOP-lowering medication for reasons other than efficacy. IOP-lowering rescue treatment is allowed if implant retreatment criteria are not met. The primary endpoint is time to retreatment/rescue after the initial implant administration analyzed with the Kaplan-Meier method. Key safety measures include treatment-emergent adverse events (TEAEs) and reading-center evaluation of central corneal endothelial cell density (CECD). Analysis of data collected through 15 September 2023 focused on outcomes after a single or two implants.
RESULTS:
In total, 441 patients received the 10-µg bimatoprost implant in the study eye on day 1 (cycle 1), 179 patients received a second administration (cycle 2), and 378 patients had at least 12 months of follow-up data available. The median time (95% confidence interval) from the first administration to a second administration or rescue was 392 (369, 485) days; the probability of not requiring retreatment or rescue by day 360 was 57.5%. A second implant administration similarly provided a long duration of IOP control. The baseline mean (standard error, SE) IOP was 25.6 (0.14) mmHg; the mean (SE) change from baseline IOP in unrescued eyes after a single administration was - 7.5 (0.21) mmHg at week 24 and - 6.4 (0.28) mmHg at month 12. Conjunctival hyperemia, typically associated with the administration procedure, was the most common ocular TEAE (cycle 1, 14.3%; cycle 2, 12.8%). Mean (SE) percentage change in CECD from baseline at 12 months after administration was - 4.3 (0.81)% in cycle 1 and - 8.5 (2.22)% in cycle 2. The cycle 1 implant was no longer visible or ≤ 25% of initial size in 66.3% and 94.3% of study eyes at months 12 and 24, respectively.
CONCLUSIONS:
In this interim analysis based on available data, the IOP-lowering effect of the initial administration of the 10-µg bimatoprost implant was well maintained for > 1 year in most patients. Results after a second administration were comparable. The safety profile of initial and repeat administration was acceptable.
TRIAL REGISTRY:
ClinicalTrials.gov identifier NCT03850782; registered 20 February 2019.
100 项与 贝美前列素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2009-07-07 | |
| 青光眼 | 日本 | 2009-07-07 | |
| 少毛症 | 美国 | 2008-12-24 | |
| 开角型青光眼 | 美国 | 2001-03-16 | |
| 高眼压症 | 美国 | 2001-03-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白内障 | 临床2期 | 美国 | 2023-10-13 | |
| 男性雄激素源性脱发 | 临床2期 | 美国 | 2013-08-01 | |
| 脱发 | 临床2期 | 美国 | 2011-06-01 | |
| 脱发 | 临床2期 | 德国 | 2011-06-01 | |
| 雄激素脱发 | 临床2期 | 美国 | 2011-06-01 | |
| 雄激素脱发 | 临床2期 | 德国 | 2011-06-01 | |
| 皮肤松弛症 | 临床1期 | 美国 | 2016-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 441 | 築遞糧構窪憲鏇觸積蓋(簾顧壓夢築網膚遞夢夢) = 顧遞簾構鹹積製鏇衊製 選蓋獵艱廠膚遞遞獵窪 (繭鏇鏇範餘鹽繭窪遞顧, 369 ~ 485) 更多 | 积极 | 2025-02-22 | |||
临床2期 | - | LL-BMT1 32-µg dose | 壓鹽構齋簾鑰餘鹹憲鹹(窪網範蓋積蓋觸衊壓鏇) = 獵構窪淵選簾積淵壓餘 憲襯範繭簾積範選餘簾 (鏇膚蓋襯艱網鏇窪衊網 ) 更多 | 积极 | 2024-11-12 | ||
bimatoprost 0.01% | - | ||||||
临床3期 | 485 | (T4032) | 艱選憲構醖鑰顧願簾顧(衊鑰衊夢蓋廠壓築繭醖) = 鹹衊壓醖餘繭鹽鹹襯蓋 顧簾鑰繭艱鑰鏇餘網艱 (鹽願構艱顧繭糧鑰蓋顧, 0.19) 更多 | - | 2023-11-21 | ||
(Lumigan®) | 艱選憲構醖鑰顧願簾顧(衊鑰衊夢蓋廠壓築繭醖) = 餘製鹽範鑰醖鹽壓簾遞 顧簾鑰繭艱鑰鏇餘網艱 (鹽願構艱顧繭糧鑰蓋顧, 0.18) 更多 | ||||||
临床3期 | 37 | (Bimatoprost SR 10 μg) | 築網鹹選範壓鬱選獵衊(齋簾觸選淵鏇夢願淵獵) = 廠窪艱鹹齋願廠廠構觸 糧遞襯餘鑰範膚顧顧鹽 (鬱醖觸積築鬱襯憲夢蓋, 5.65) 更多 | - | 2023-06-08 | ||
(LUMIGAN 0.01%) | 築網鹹選範壓鬱選獵衊(齋簾觸選淵鏇夢願淵獵) = 齋觸獵淵簾築鬱顧觸顧 糧遞襯餘鑰範膚顧顧鹽 (鬱醖觸積築鬱襯憲夢蓋, 5.27) 更多 | ||||||
临床3期 | - | 壓願衊壓鹹網網鏇簾選(憲廠獵積鏇膚選願醖膚) = 鹽築衊築齋範製夢觸築 憲餘積繭築餘糧繭襯選 (鹹範窪鹹製獵遞鑰壓壓 ) | - | 2022-05-28 | |||
Topical timolol maleate 0.5% | 壓願衊壓鹹網網鏇簾選(憲廠獵積鏇膚選願醖膚) = 艱積糧製鏇襯蓋觸積襯 憲餘積繭築餘糧繭襯選 (鹹範窪鹹製獵遞鑰壓壓 ) | ||||||
临床3期 | 203 | 鏇醖蓋淵顧淵選淵積觸(鹹繭膚醖獵廠簾範餘選) = 積窪範廠衊窪鹹積觸鑰 願膚鏇築觸築觸範衊餘 (淵淵範顧艱遞鹽觸壓夢 ) | - | 2022-05-01 | |||
N/A | 122 | Bimatoprost SR implantation | 廠築淵繭衊簾夢願簾艱(鑰齋蓋壓膚築齋鑰糧選) = 憲壓醖齋夢鏇襯觸鏇餘 糧壓廠鏇窪獵構鏇獵觸 (廠築願簾壓糧鬱鑰選餘 ) | - | 2022-05-01 | ||
N/A | - | - | Bimatoprost free acid | 顧積範窪範顧蓋夢築遞(選壓獵顧網鏇襯餘壓鹹) = a dose-dependent although non-statistically significant increase in protein expression with a maximal increase of 56% 鏇製觸構築選鑰觸憲蓋 (窪簾鑰廠鏇繭選願製齋 ) 更多 | - | 2022-05-01 | |
N/A | 122 | Bimatoprost SR | 遞獵鏇蓋膚艱鬱衊醖鏇(構範糧鏇鬱蓋蓋蓋膚醖) = 淵憲範構繭膚壓壓鏇鑰 繭鹽餘餘壓醖齋鏇糧餘 (齋餘鹹範憲壓鹹艱襯顧 ) | - | 2022-05-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用